Targeting IL-25 as a novel therapy in chronic rhinosinusitis with nasal polyps

Current Opinion in Allergy and Clinical Immunology

Volumn 17, Issue 1, 2017, Pages 17-22

  Lee, Mingyu ^a,b   Kim, Dae Woo ^c,d   Shin, Hyun Woo ^a,b,d,e  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Clinical Mucosal Immunology Study Group   (South Korea)

^e Seoul National University Hospital   (South Korea)

Author keywords

Allergy; Chronic rhinosinusitis; IL 25; Nasal polyps; Therapeutic target

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 25; INTERLEUKIN 25 NEUTRALIZING ANTIBODY; INTERLEUKIN 33; NEUTRALIZING ANTIBODY; THYMIC STROMAL LYMPHOPOIETIN; UNCLASSIFIED DRUG; IL25 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

CHRONIC RHINOSINUSITIS; DRUG EFFECT; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOSE POLYP; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; ANIMAL; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; NASAL POLYPS; PROCEDURES; RHINITIS; SINUSITIS; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; MOLECULAR TARGETED THERAPY; NASAL POLYPS; RHINITIS; SINUSITIS;

EID: 84996605746     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000332     Document Type: Review

References (69)

1. Casale M, Pappacena M, Potena M, et al. Nasal polyposis: From pathogenesis to treatment, an update. Inflamm Allergy Drug Targets 2011; 10: 158-163.
2. Hamilos DL. Chronic rhinosinusitis: Epidemiology and medical management. J Allergy Clin Immunol 2011; 128: 693-707.
3. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50: 1-12.
4. Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of chronic rhinosinusitis: Inflammation. J Allergy Clin Immunol 2011; 128: 728-732.
5. Lam K, Kern RC, Luong A. Is there a future for biologics in the management of chronic rhinosinusitis? Int Forum Allergy Rhinol 2016; 6: 935-942.
6. Hamilos DL. Drivers of chronic rhinosinusitis: Inflammation versus infection. J Allergy Clin Immunol 2015; 136: 1454-1459.
7. Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 2008; 122: 961-968.
8. Mygind N, Dahl R, Bachert C. Nasal polyposis, eosinophil dominated inflammation, and allergy. Thorax 2000; 55 (Suppl 2): S79-S83.
9. Petersen BC, Lukacs NW. IL-17A and IL-25: Therapeutic targets for allergic and exacerbated asthmatic disease. Future Med Chem 2012; 4: 833-836.
10. Divekar R, Kita H. Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr Opin Allergy Clin Immunol 2015; 15: 98-103.
11. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-162.
12. Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001; 15: 985-995.
13. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009; 31: 425-437.
14. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: Regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12: 21-27.
15. Shin HW, Kim DK, Park MH, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2015; 135: 1476-1485; e1477.
16. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006; 61: 1280-1289.
17. Lund S, Walford HH, Doherty TA. Type 2 innate lymphoid cells in allergic disease. Curr Immunol Rev 2013; 9: 214-221.
18. Wynn TA. Type 2 cytokines: Mechanisms and therapeutic strategies. Nat Rev Immunol 2015; 15: 271-282.
19. Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013; 14: 536-542.
20. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol 2012; 130: 845-852.
21. Comeau MR, Ziegler SF. The influence of TSLP on the allergic response. Mucosal Immunol 2010; 3: 138-147.
22. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 2015; 75: 14-24.
23. Allakhverdi Z, Comeau MR, Smith DE, et al. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009; 123: 472-478.
24. Liu T, Li TL, Zhao F, et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. Am J Med Sci 2011; 341: 40-47.
25. Kimura S, Pawankar R, Mori S, et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res 2011; 3: 186-193.
26. Ouyang Y, Fan E, Li Y, et al. Clinical characteristics and expression of thymic stromal lymphopoetin in eosinophilic and noneosinophilic chronic rhinosinusitis. ORL J Otorhinolaryngol Relat Spec 2013; 75: 37-45.
27. Boita MGM, Raimondo L, Riva G, et al. Eosinophilic inflammation of chronic rhinosinusitis with nasal polyps is related to OX40 ligand expression. Innate Immnun 2015; 21: 167-174.
28. Kato A, Favoreto S Jr, Avila PC, Schleimer RP. TLR3-and Th2 cytokinedependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol 2007; 179: 1080-1087.
29. Kato A, Schleimer RP. Beyond inflammation: Airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol 2007; 19: 711-720.
30. Kouzaki H, O'Grady SM, Lawrence CB, Kita H. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through proteaseactivated receptor-2. J Immunol 2009; 183: 1427-1434.
31. Bal SM, Bernink JH, Nagasawa M, et al. IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol 2016; 17: 636-645.
32. Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2013; 132: 593-600; e512.
33. Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370: 2102-2110.
34. Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 2011; 186: 4375-4387.
35. Baba S, Kondo K, Kanaya K, et al. Expression of IL-33 and its receptor ST2 in chronic rhinosinusitis with nasal polyps. Laryngoscope 2014; 124: E115-E122.
36. Shaw JL, Fakhri S, Citardi MJ, et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med 2013; 188: 432-439.
37. Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol 2014; 134: 671-678; e674.
38. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009; 179: 772-781.
39. Kim YH, Yang TY, Park CS, et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012; 67: 183-190.
40. Liu X, Li M, Wu Y, et al. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009; 386: 181-185.
41. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20: 791-800.
42. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
43. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476.
44. Kouzaki H, Tojima I, Kita H, Shimizu T. Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells. Am J Respir Cell Mol Biol 2013; 49: 741-750.
45. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-567.
46. Rickel EASL, Yoon BR, Rottman JB, et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 2008; 181: 4299-4310.
47. Swaidani S, Bulek K, Kang Z, et al. The critical role of epithelial-derived Act1 in IL-17-and IL-25-mediated pulmonary inflammation. J Immunol 2009; 182: 1631-1640.
48. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: Regulation and function in innate immunity. Cytokine Growth Factor Rev 2010; 21: 413-423.
49. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int 2015; 64: 121-130.
50. Angkasekwinai P, Park H, Wang YH, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 2007; 204: 1509-1517.
51. Kato T, Kouzaki H, Matsumoto K, et al. The effect of calprotectin on TSLP and IL-25 production from airway epithelial cells. Allergol Int 2016. [Epub ahead of print]
52. Lam M, Hull L, McLachlan R, et al. Clinical severity and epithelial endotypes in chronic rhinosinusitis. Int Forum Allergy Rhinol 2013; 3: 121-128.
53. Lam EP, Kariyawasam HH, Rana BM, et al. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol 2016; 137: 1514-1524.
54. Tang W, Smith SG, Beaudin S, et al. IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int Arch Allergy Immunol 2014; 163: 5-10.
55. Miljkovic D, Bassiouni A, Cooksley C, et al. Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis. Allergy 2014; 69: 1154-1161.
56. Iinuma T, Okamoto Y, Yamamoto H, et al. Interleukin-25 and mucosal T cells in noneosinophilic and eosinophilic chronic rhinosinusitis. Ann Allergy Asthma Immunol 2015; 114: 289-298.
57. Liao B, Cao PP, Zeng M, et al. Interaction of thymic stromal lymphopoietin, IL-33, and their receptors in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps. Allergy 2015; 70: 1169-1180.
58. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells -A proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-149.
59. Sonnenberg GF, Mjosberg J, Spits H, Artis D. SnapShot: Innate lymphoid cells. Immunity 2013; 39: 622-622; e621.
60. Moro K, Yamada T, Tanabe M, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010; 463: 540-544.
61. Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12: 1055-1062.
62. Salimi M, Barlow JL, Saunders SP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 2013; 210: 2939-2950.
63. Mjosberg J, Bernink J, Golebski K, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012; 37: 649-659.
64. Walford HH, Lund SJ, Baum RE, et al. Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness. Clin Immunol 2014; 155: 126-135.
65. Matsushita K, Kato Y, Akasaki S, Yoshimoto T. Proallergic cytokines and group 2 innate lymphoid cells in allergic nasal diseases. Allergol Int 2015; 64: 235-240.
66. Gregory LG1 JC,WalkerSA, Sawant D, et al. IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax 2013; 1: 82-90.
67. Camelo A1 BJ, Drynan LF, Neill DR, et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol 2012; 11: 1198-1211.
68. Ballantyne SJ, Barlow JL, Jolin HE, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2007; 120: 1324-1331.
69. Fallon PG, Ballantyne SJ, Mangan NE, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med 2006; 203: 1105-1116.